ONCOcept Heam DNA Genetic Test in Lahore at Chughtai Lab

ONCOcept Heam DNA by Gene Tech at Chughtai Lab

The ONCOcept Heam DNA panel, developed by Gene Tech and offered through Chughtai Lab, is a highly specialized molecular diagnostic test designed to analyze the genetic landscape of hematological malignancies. This advanced molecular assay utilizes state-of-the-art technology, including Next-Generation Sequencing (NGS) and multiplex Polymerase Chain Reaction (PCR), to detect somatic mutations, gene fusions, and chromosomal rearrangements. These genetic aberrations are the driving forces behind various blood cancers, including acute leukemias, chronic leukemias, myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN). By identifying these specific molecular markers, the test provides clinicians with critical insights necessary for accurate disease classification, prognostic stratification, and the selection of targeted therapies.

The clinical importance of the ONCOcept Heam DNA test lies in its ability to detect submicroscopic genetic alterations that traditional cytogenetics and karyotyping might miss. The test evaluates DNA and RNA extracted from peripheral blood or bone marrow aspirates, targeting key genes involved in hematopoietic cell differentiation, proliferation, and survival. This comprehensive molecular profiling is essential for precision medicine in hematology. For instance, identifying specific mutations like FLT3, NPM1, or JAK2 directly influences treatment protocols, helping oncologists decide between standard chemotherapy, targeted inhibitors, or hematopoietic stem cell transplantation. Ultimately, this test serves as an indispensable tool for establishing a definitive diagnosis, monitoring minimal residual disease (MRD), and predicting patient outcomes.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is essential to ensure sample integrity and accurate molecular analysis. Patients undergoing the ONCOcept Heam DNA test should observe the following guidelines:

No Fasting Required: Routine fasting is not necessary for this test. Patients can eat and drink normally prior to sample collection.
Clinical Documentation: Patients must provide a complete clinical history, including previous Complete Blood Count (CBC) reports, bone marrow biopsy findings, and details of any ongoing or past chemotherapy or targeted therapies.
Informed Consent: Since this is a specialized genetic and molecular test, patients or their legal guardians are required to sign an informed consent form before sample collection.
Blood Transfusion History: Inform the laboratory staff if you have received a blood transfusion recently, as donor DNA can temporarily interfere with molecular testing results.
Medication History: Provide a complete list of all medications, especially immunosuppressants, chemotherapy agents, or anticoagulants, to the laboratory physician.

During the Procedure

The sample collection process is straightforward and adheres to strict clinical protocols to prevent contamination and sample degradation:

Sample Source: The test can be performed on either a peripheral blood sample or a bone marrow aspirate, depending on the referring physician’s instructions.
Peripheral Blood Collection: A phlebotomist will perform a standard venipuncture, typically drawing blood from a vein in your arm into a sterile EDTA (purple top) tube. This process takes approximately 2 to 5 minutes.
Bone Marrow Collection: If a bone marrow sample is required, it must be collected by a qualified hematologist or oncologist at a clinical facility. The collected aspirate is then immediately transferred into appropriate transport media provided by Chughtai Lab.
Aseptic Technique: Strict sterile techniques are maintained throughout the collection process to ensure the sample remains free from external bacterial or environmental DNA contamination.
Post-Collection Care: For venipuncture, a small bandage is applied to the site. Patients can resume their daily activities immediately after the blood draw.

When is a ONCOcept Heam DNA Test Performed?

Acute Myeloid Leukemia (AML) Diagnosis and Risk Stratification

Acute Myeloid Leukemia is a rapid-onset cancer of the myeloid blood cells characterized by symptoms such as severe fatigue, easy bruising, frequent infections, and unexplained fever. Physicians request the ONCOcept Heam DNA test at the time of suspected AML diagnosis to identify key mutations in genes such as FLT3, NPM1, CEBPA, and IDH1/IDH2. Identifying these mutations is critical because they define the molecular subtype of the leukemia according to World Health Organization (WHO) guidelines, establish whether the patient has a favorable, intermediate, or adverse prognosis, and determine eligibility for targeted therapies like FLT3 inhibitors or IDH inhibitors.

Chronic Myeloid Leukemia (CML) Monitoring and Resistance Detection

Chronic Myeloid Leukemia is characterized by the unregulated growth of myeloid cells, often presenting with splenomegaly, night sweats, and weight loss. The hallmark of CML is the BCR-ABL1 fusion gene, also known as the Philadelphia chromosome. Clinicians order this molecular test to monitor the levels of the BCR-ABL1 transcript in patients undergoing Tyrosine Kinase Inhibitor (TKI) therapy. If a patient shows signs of treatment resistance or disease progression, the test helps identify specific kinase domain mutations (such as T315I) that render certain TKIs ineffective, guiding the selection of alternative therapies.

Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) Evaluation

Myelodysplastic Syndromes and Myeloproliferative Neoplasms are clonal hematopoietic stem cell disorders characterized by cytopenias or overproduction of mature blood cells, leading to symptoms like anemia, thrombosis, or splenomegaly. Physicians utilize the ONCOcept Heam DNA panel to detect driver mutations in JAK2, CALR, and MPL, as well as secondary mutations in ASXL1, TET2, or SRSF2. Detecting these mutations helps differentiate clonal hematological disorders from reactive non-cancerous conditions, confirms the diagnosis of Polycythemia Vera, Essential Thrombocythemia, or Primary Myelofibrosis, and assesses the risk of transformation into acute leukemia.

Acute Lymphoblastic Leukemia (ALL) Subtyping

Acute Lymphoblastic Leukemia is a fast-growing cancer of the lymphoid progenitor cells, commonly affecting children and young adults, presenting with lymphadenopathy, bone pain, and bleeding tendencies. The ONCOcept Heam DNA test is performed to detect crucial genetic rearrangements, such as BCR-ABL1, KMT2A (MLL) rearrangements, or ETV6-RUNX1 fusions. These molecular findings are vital for risk-adapted therapy, helping clinicians decide on the intensity of chemotherapy protocols and identify candidates for targeted monoclonal antibody therapies or bone marrow transplantation.

Chronic Lymphocytic Leukemia (CLL) Prognostication

Chronic Lymphocytic Leukemia is a slow-growing cancer of B-lymphocytes, often diagnosed incidentally or during investigations for painless lymph node enlargement and persistent lymphocytosis. Physicians request this molecular panel to evaluate the mutational status of the immunoglobulin heavy chain variable (IGHV) region and to detect TP53 mutations or deletions. Patients with unmutated IGHV or TP53 aberrations tend to have a more aggressive disease course, and these findings guide the transition from a watch-and-wait approach to active treatment with novel targeted agents like BTK inhibitors.

What Does a ONCOcept Heam DNA Test Detect?

The ONCOcept Heam DNA panel is designed to detect a wide range of clinically significant genetic alterations, including:

BCR-ABL1 fusion transcripts associated with CML and Philadelphia chromosome-positive ALL.
PML-RARA fusion transcripts diagnostic of Acute Promyelocytic Leukemia (APL).
RUNX1-RUNX1T1 fusion transcripts associated with core-binding factor AML.
CBFB-MYH11 fusion transcripts indicative of inv(16) AML.
FLT3 Internal Tandem Duplications (FLT3-ITD), a high-risk prognostic marker in AML.
FLT3 Tyrosine Kinase Domain (FLT3-TKD) point mutations.
NPM1 mutations, which represent a favorable prognostic marker in AML when FLT3-ITD is absent.
CEBPA double mutations, associated with a favorable prognosis in AML.
JAK2 V617F mutation, the primary driver in Polycythemia Vera, Essential Thrombocythemia, and Myelofibrosis.
JAK2 Exon 12 mutations, found in JAK2 V617F-negative Polycythemia Vera.
CALR Exon 9 insertions and deletions in JAK2-negative MPNs.
MPL W515L/K mutations associated with Essential Thrombocythemia and Myelofibrosis.
TP53 somatic mutations, indicating resistance to standard chemotherapy across multiple hematological cancers.
IDH1 and IDH2 mutations, which serve as therapeutic targets in AML.
ASXL1 mutations, associated with poor prognosis in MDS and AML.
DNMT3A mutations, commonly involved in clonal hematopoiesis and early leukemogenesis.
TET2 mutations, affecting DNA methylation in myeloid malignancies.
RUNX1 point mutations, associated with familial platelet disorders and secondary AML.
KIT mutations, particularly in core-binding factor AML, indicating a higher risk of relapse.
CSF3R mutations, highly specific for Chronic Neutrophilic Leukemia (CNL).
SF3B1 mutations, strongly associated with MDS characterized by ring sideroblasts.
SRSF2 mutations, indicating splicing factor abnormalities in MDS and CMML.
U2AF1 mutations, another common splicing factor mutation in myeloid disorders.
ZRSR2 mutations, involved in RNA splicing defects.
BRAF V600E mutation, diagnostic for Hairy Cell Leukemia.
MYD88 L265P mutation, highly sensitive and specific for Waldenström Macroglobulinemia.
IGHV somatic hypermutation status in CLL.
KMT2A (MLL) gene rearrangements, indicating high-risk leukemia.
ETV6-RUNX1 fusion transcripts, a favorable prognostic marker in pediatric B-ALL.
TCF3-PBX1 fusion transcripts, associated with pre-B-ALL.

Turnaround Time and Report Access at Chughtai Lab

Because the ONCOcept Heam DNA test involves highly complex molecular biology workflows, including DNA/RNA extraction, amplification, sequencing, and bioinformatic analysis, the turnaround time is longer than routine blood tests. Typically, reports are finalized within 10 to 14 working days. Once the analysis is complete, the raw data is interpreted by a team of qualified molecular geneticists and consultant pathologists at Chughtai Lab to ensure maximum clinical accuracy.

Patients and referring physicians can easily access the reports digitally. Chughtai Lab provides multiple convenient ways to retrieve results, including the official Chughtai Lab website portal and the My Chughtai mobile application. Additionally, patients can opt to receive their reports via email or WhatsApp, or they can collect a printed copy from any of the numerous Chughtai Lab collection centers located across Pakistan.

ONCOcept Heam DNA Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
BCR-ABL1 Fusion	Not Detected	Detected (Diagnostic for CML or Ph+ ALL)
JAK2 V617F Mutation	Not Detected	Detected (Associated with Polycythemia Vera, ET, or Myelofibrosis)
FLT3-ITD Mutation	Not Detected	Detected (Indicates high-risk AML; guides FLT3 inhibitor therapy)
NPM1 Mutation	Not Detected	Detected (Associated with favorable prognosis in AML if FLT3-ITD is negative)
CALR Exon 9 Mutation	Not Detected	Detected (Associated with JAK2-negative ET or Myelofibrosis)
TP53 Mutation	Not Detected	Detected (Associated with chemotherapy resistance and poor prognosis)
PML-RARA Fusion	Not Detected	Detected (Diagnostic for Acute Promyelocytic Leukemia; requires urgent therapy)
MYD88 L265P Mutation	Not Detected	Detected (Highly suggestive of Waldenström Macroglobulinemia)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for ONCOcept Heam DNA?

Experienced Healthcare Professionals: Chughtai Lab employs highly qualified consultant pathologists, hematologists, and molecular geneticists to oversee all testing and reporting.
Patient-Focused Care: The lab prioritizes patient comfort, safety, and clear communication throughout the diagnostic journey.
Quality Diagnostic Services: Operating with international quality standards and participating in rigorous external proficiency testing programs.
Professional Reporting: Detailed molecular reports include clinical correlation and therapeutic implications to assist oncologists in decision-making.
Modern Diagnostic Approach: Utilizing state-of-the-art molecular biology equipment and advanced sequencing technologies in partnership with Gene Tech.
Comfortable Environment: All collection centers are designed to provide a clean, sterile, and welcoming environment for patients.
Convenient Location: With a vast network of collection centers across Lahore and nationwide, accessing services is highly convenient.
Commitment to Accurate Diagnosis: Dedicated to delivering precise, reproducible, and timely genetic insights to support effective cancer treatment.

Frequently Asked Questions (FAQs)

What is the ONCOcept Heam DNA test?

The ONCOcept Heam DNA test is a advanced molecular diagnostic panel developed by Gene Tech and offered at Chughtai Lab. It analyzes DNA and RNA from blood or bone marrow samples to detect genetic mutations, fusions, and rearrangements associated with blood cancers, such as leukemia, lymphoma, and myeloproliferative disorders. This genetic profiling helps doctors accurately diagnose the disease, predict its course, and choose targeted treatments.

Why do doctors recommend this test for leukemia patients?

Doctors recommend this test because blood cancers are highly variable at the genetic level. Traditional tests like microscopical examinations cannot identify specific gene mutations. The ONCOcept Heam DNA test identifies precise molecular markers, which are essential for determining whether a patient has a high-risk or low-risk form of leukemia. This information allows oncologists to customize treatment plans, select targeted therapies, and monitor how well the patient is responding to treatment.

Is fasting required before sample collection?

No, fasting is not required for the ONCOcept Heam DNA test. You can eat, drink, and take your routine medications normally before your sample is collected. However, it is highly important to inform the laboratory staff about your complete medical history, any recent blood transfusions, and any chemotherapy or targeted cancer therapies you are currently receiving, as these factors can influence the analysis of your genetic sample.

How long does it take to get the ONCOcept Heam DNA report?

Due to the highly complex nature of molecular genetic testing, which involves DNA extraction, amplification, sequencing, and detailed bioinformatic analysis, the turnaround time for the ONCOcept Heam DNA test is typically 10 to 14 working days. The results are carefully reviewed and signed off by qualified molecular pathologists and consultant hematologists at Chughtai Lab to ensure the highest level of clinical accuracy and reliability.

How can I access my test results from Chughtai Lab?

Chughtai Lab offers multiple convenient digital and physical options to access your reports. You can view and download your report online through the official Chughtai Lab website portal or by using the My Chughtai mobile application on your smartphone. Additionally, reports can be sent directly to your registered email address or WhatsApp number, or you can collect a printed copy from any Chughtai Lab collection center.